Online citations, reference lists, and bibliographies.

Cost-effectiveness Of Hypertension Therapy According To 2014 Guidelines.

Andrew E Moran, Michelle Odden, Anusorn Thanataveerat, Keane Y. Tzong, Petra W. Rasmussen, David Guzman, Lawrence Williams, Kirsten Bibbins-Domingo, Pamela G. Coxson, Lee Goldman
Published 2015 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND On the basis of the 2014 guidelines for hypertension therapy in the United States, many eligible adults remain untreated. We projected the cost-effectiveness of treating hypertension in U.S. adults according to the 2014 guidelines. METHODS We used the Cardiovascular Disease Policy Model to simulate drug-treatment and monitoring costs, costs averted for the treatment of cardiovascular disease, and quality-adjusted life-years (QALYs) gained by treating previously untreated adults between the ages of 35 and 74 years from 2014 through 2024. We assessed cost-effectiveness according to age, hypertension level, and the presence or absence of chronic kidney disease or diabetes. RESULTS The full implementation of the new hypertension guidelines would result in approximately 56,000 fewer cardiovascular events and 13,000 fewer deaths from cardiovascular causes annually, which would result in overall cost savings. The projections showed that the treatment of patients with existing cardiovascular disease or stage 2 hypertension would save lives and costs for men between the ages of 35 and 74 years and for women between the ages of 45 and 74 years. The treatment of men or women with existing cardiovascular disease or men with stage 2 hypertension but without cardiovascular disease would remain cost-saving even if strategies to increase medication adherence doubled treatment costs. The treatment of stage 1 hypertension was cost-effective (defined as <$50,000 per QALY) for all men and for women between the ages of 45 and 74 years, whereas treating women between the ages of 35 and 44 years with stage 1 hypertension but without cardiovascular disease had intermediate or low cost-effectiveness. CONCLUSIONS The implementation of the 2014 hypertension guidelines for U.S. adults between the ages of 35 and 74 years could potentially prevent about 56,000 cardiovascular events and 13,000 deaths annually, while saving costs. Controlling hypertension in all patients with cardiovascular disease or stage 2 hypertension could be effective and cost-saving. (Funded by the National Heart, Lung, and Blood Institute and others.).
This paper references
Blood pressure in young adulthood and mortality from cardiovascular disease
J C Greatrex (2000)
10.1136/bmj.326.7404.1427
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials
Malcolm R Law (2003)
10.1001/archinte.162.5.610
Blood pressure in early life and cardiovascular disease mortality.
Peter McCarron (2002)
10.1001/jama.2013.13805
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors.
Christopher J. L. Murray (2013)
10.1016/S0140-6736(14)61212-5
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
Johan Sundström (2014)
10.1377/hlthaff.26.1.97
The value of antihypertensive drugs: a perspective on medical innovation.
David M. Cutler (2007)
10.3122/jabfm.12.2.105
An Economic Evaluation of the JNC Hypertension Guidelines Using Data From a Randomized Controlled Trial
Shaun D. Ramsey (1999)
10.1161/CIR.0000000000000042
ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.
Jeffrey L. Anderson (2014)
Medicine Downloaded from nejm.org at UNIVERSITY OF CALGARY on For personal use only. No other uses without permission. Copyright © 2015 Massachusetts Medical Society
(2015)
10.1186/1478-7547-11-6
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
Don Husereau (2013)
10.1001/jama.289.16.2083
Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial.
Lawrence J. Appel (2003)
National Health and Nutrition Survey home page
MR Law
10.1001/jama.2013.284427
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
Paul A. James (2014)
Copyright © 2015 Massachusetts Medical Society
10.1111/j.1475-6773.2009.01075.x
Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes.
Justin W. Timbie (2010)
vard Alumni Health Study)
(2011)
10.1001/jama.2013.108769
Improved blood pressure control associated with a large-scale hypertension program.
Marc G Jaffe (2013)
10.1007/s11606-008-0515-2
Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Paul A. Heidenreich (2008)
10.18553/jmcp.2003.9.1.53
Examining the value and quality of health economic analyses: implications of utilizing the QHES.
Joshua J. Ofman (2003)
10.7326/M13-2981
Evidence Supporting a Systolic Blood Pressure Goal of Less Than 150 mm Hg in Patients Aged 60 Years or Older: The Minority View
Jackson T. Wright (2014)
10.1001/archinte.161.12.1501
Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry.
Katsuki Miura (2001)
10.1001/jama.2014.2531
Proportion of US adults potentially affected by the 2014 hypertension guideline.
Ann Marie Navar-Boggan (2014)
Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC
PA James (2014)
Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving
10.1371/journal.pmed.1000058
The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle, and Metabolic Risk Factors
Goodarz Danaei (2009)
10.1001/jama.289.19.2560
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report
Aram V. Chobanian (2003)
10.1002/14651858.cd005182.pub3
Interventions used to improve control of blood pressure in patients with hypertension.
Tom Fahey (2006)
10.1136/bmj.b1665
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
Malcolm R Law (2009)
10.1016/s0140-6736(03)14739-3
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.
Fiona M Turnbull (2003)
10.1016/j.jacc.2011.07.045
Blood pressure in early adulthood, hypertension in middle age, and future cardiovascular disease mortality: HAHS (Harvard Alumni Health Study).
Linsay Gray (2011)
10.1056/NEJM199704173361601
A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group.
Lawrence J. Appel (1997)
Average wholesale price ( AWP ) policy
LG Glynn (2014)
10.1161/HYP.0000000000000003
An Effective Approach to High Blood Pressure Control: A Science Advisory From the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention
Alan S. Go (2014)
10.1111/j.1532-5415.1988.tb04370.x
Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older. The Framingham Heart Study.
Tamara B. Harris (1988)
10.7326/0003-4819-154-9-201105030-00008
Individualized Guidelines: The Potential for Increasing Quality and Reducing Costs
David M. Eddy (2011)
10.1016/S0140-6736(02)11911-8
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
Konrad Jamrozik (2002)
10.1161/CIRCULATIONAHA.113.002290
Using Benefit-Based Tailored Treatment to Improve the Use of Antihypertensive Medications
Jeremy B. Sussman (2013)



This paper is referenced by
Comparative cost-effectiveness of conservative or intensive blood pressure treatment guidelines in adults aged 35-74 years : the CVD Policy Model
Nathalie Moise (2016)
10.1093/gerona/glw181
The Relationship Between Cognitive Functioning and the JNC-8 Guidelines for Hypertension in Older Adults
Felicia C. Goldstein (2017)
10.1371/journal.pone.0225207
An acceleration in hypertension-related mortality for middle-aged and older Americans, 1999-2016: An observational study
Steven J Forrester (2020)
10.1161/CIRCULATIONAHA.115.018912
Global Disparities of Hypertension Prevalence and ControlClinical Perspective
Katherine T. Mills (2016)
10.1136/bmjopen-2015-010806
Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment
Edo Richard (2016)
Investing in the health of the 41-60 year old : reaping the return in the 60+ population?
Antonella Sammut (2016)
10.1001/jamacardio.2016.3517
Cost-effectiveness of Intensive Blood Pressure Management.
Ilana B Richman (2016)
10.1016/j.biopha.2017.10.095
Taurine enhances spermatogenic function and antioxidant defense mechanisms in testes and epididymis of L-NAME-induced hypertensive rats.
Isaac A. Adedara (2018)
10.1056/NEJMsa1616035
Cost‐Effectiveness of Intensive versus Standard Blood‐Pressure Control
Adam P Bress (2017)
10.1002/ptr.6362
Does ginger supplementation lower blood pressure? A systematic review and meta-analysis of clinical trials.
Hossein Hasani (2019)
10.1007/s11606-019-05396-7
Hypertension Self-management in Socially Disadvantaged African Americans: the Achieving Blood Pressure Control Together (ACT) Randomized Comparative Effectiveness Trial
L. Ebony Boulware (2019)
10.1161/HYPERTENSIONAHA.115.03622
Nox and Inflammation in the Vascular Adventitia.
Daniel N. Meijles (2016)
Mechanisms of Biomaterial-Mediated Cardiac and Esophageal Repair
Ricardo Londono (2015)
10.1016/j.cnur.2015.05.002
Cardiovascular Health Among an Underserved Population: Clinical Implications.
Margaret T. Bowers (2015)
10.1080/24725854.2018.1499053
Optimal coinsurance rates for a heterogeneous population under inequality and resource constraints
Greggory J. Schell (2019)
10.1371/journal.pone.0211032
The effect of exercise on blood pressure in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials
Stephanie Thompson (2019)
Estimating the Optimal Individualized Treatment Rule from A Cost-Effectiveness Perspective
Yuzhen Xu (2020)
Measuring Adherence to Evidence-Based Practice Guidelines for the Management of Hypertension in Women
Cristina M Jorgensen (2015)
10.1186/s13561-016-0119-1
Health expenditures spent for prevention, economic performance, and social welfare
Fuhmei Wang (2016)
10.11591/IJPHS.V8I1.15240
Adherence and quality of life among diabetic patients with hypertension
Akrom Akrom (2018)
10.1177/1062860620910200
Hypertension and Diabetes Quality Improvement in a Practice Transformation Network.
Niharika Khanna (2020)
10.1136/bmjopen-2018-025819
Self-management and blood pressure control in China: a community-based multicentre cross-sectional study
Zhan Qu (2019)
10.1177/2047487317730472
Preventing cardiovascular disease after hypertensive disorders of pregnancy: Searching for the how and when
T Katrien J Groenhof (2017)
10.1001/jama.2015.10082
Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage.
Alessandro Biffi (2015)
Hypertension: Enhancing Lifestyle Management Through Patient Education and Pender’s Health Promotion Model
Katherine Z Holcomb (2017)
Patellofemoral Pain : Unravelling its Course and Treatment
Nienke E Lankhorst (2015)
10.1016/j.amjmed.2017.07.018
Making Cardiovascular Care More Responsive to Societal Needs.
William S Weintraub (2017)
10.1371/journal.pmed.1002158
Projected Impact of Mexico’s Sugar-Sweetened Beverage Tax Policy on Diabetes and Cardiovascular Disease: A Modeling Study
Luz María Sánchez-Romero (2016)
10.15406/jccr.2017.10.00353
Hypertension; East and West
Abdul Rashid Abdul Rahman (2017)
The Effect of Long-term Aerobic Exercise and Training Intensity on Blood Pressure in the Elderly
Emma Ingeström (2018)
10.22371/07.2017.024
Effects of Hypertension Education and Motivation Interviewing by Staff on Patients' Activation
Tammy C. Lu (2017)
10.1161/HYPERTENSIONAHA.115.06857
Evidence to Maintain the Systolic Blood Pressure Treatment Threshold at 140 mm Hg for Stroke Prevention: The Northern Manhattan Study
Chuanhui Dong (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar